Skip to main content

Lupkynis Disease Interactions

There are 8 disease interactions with Lupkynis (voclosporin).

Major

Immunosuppressive agents (applies to Lupkynis) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

References

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories (2001):
  2. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  3. "Product Information. BENLYSTA (belimumab)." GlaxoSmithKline (2011):
  4. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  5. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  6. "Product Information. Tecfidera (dimethyl fumarate)." Biogen (2013):
  7. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  8. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
  9. "Product Information. Gamifant (emapalumab)." Sobi Inc (2018):
  10. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
  11. "Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals (2021):
View all 11 references
Major

Voclosporin (applies to Lupkynis) liver dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Voclosporin is predominantly metabolized by CYP450 3A4. Avoid the use of voclosporin in patients with severe hepatic impairment (Child-Pugh C). It is recommended to reduce the dose of voclosporin to 15.8 mg twice a day in patients with mild and moderate hepatic impairment (Child-Pugh A and Child-Pugh B).

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
Moderate

Voclosporin (applies to Lupkynis) nephrotoxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The use of voclosporin, like other calcineurin-inhibitors, can cause acute and/or chronic nephrotoxicity. Voclosporin use is not recommended in patients with a baseline estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or less unless the benefit exceeds the risk. A reduced dose should be used when treating patients with severe renal impairment at baseline. No dosage adjustment is recommended in patients with mild or moderate renal impairment at baseline. It is recommended to establish a baseline eGFR and regularly monitor eGFR during treatment. Consideration should be given to the risks and benefits of voclosporin treatment in light of the patient's treatment response and risk of worsening nephrotoxicity. Consider dose reduction or discontinuation in patients with decreases in eGFR from baseline. Persistent decrease of eGFR should be evaluated for chronic calcineurin-inhibitor nephrotoxicity.

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
Moderate

Voclosporin (applies to Lupkynis) neurotoxicities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neurologic Disorder, Posterior Reversible Encephalopathy Syndrome, Psychosis, Seizures

The use of voclosporin may cause a spectrum of neurotoxicities. It is recommended to monitor for neurologic symptoms and to consider dosage reduction or discontinuation if neurotoxicity occurs. Care should be exercised when using this drug in patients with preexisting neurological conditions such as seizures, delirium, posterior reversible encephalopathy syndrome.

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
Moderate

Voclosporin (applies to Lupkynis) PRCA

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Pure Red Cell Aplasia

Calcineurin-inhibitors, may cause pure red cell aplasia (PRCA). Care should be exercised when using voclosporin in patients at risk for PRCA, such as parvovirus B19 infection, underlying disease, or concomitant medications associated with PRCA. It is recommended to consider treatment discontinuation if PRCA is diagnosed.

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
Moderate

Voclosporin (applies to Lupkynis) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias

The use of voclosporin prolongs the QTc interval in a dose-dependent manner. Studies have demonstrated that after a single dose administration at a dose higher than the recommended lupus nephritis therapeutic dose, dose-dependent QT prolongation effect was observed. Care is recommended when using this drug in patients at risk, such as patients taking concomitant drugs known to prolong the QTc interval, patients with bradycardia, hypokalemia, or hypomagnesemia, and the presence of congenital prolongation of the QT interval. Consider obtaining electrocardiograms and monitoring electrolytes in patients at high risk.

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
Moderate

Voclosporin (applies to Lupkynis) vaccination

Moderate Potential Hazard, Moderate plausibility.

The use of live vaccines should be avoided during treatment with voclosporin, including but not limited to the intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines. In addition, inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment with voclosporin.

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
Moderate

Voclosporin – hypertension

Moderate Potential Hazard, Moderate plausibility.

The use of voclosporin causes hypertension. Exercise care when using this agent in hypertensive patients, including patients on antihypertensive drugs. It is recommended to monitor blood pressure regularly during treatment and treat new-onset hypertension and exacerbations of preexisting hypertension according to medical practices. If a patient experiences increases in blood pressure that cannot be managed with dose reduction or other appropriate medical intervention, consider treatment discontinuation.

References

  1. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):

Lupkynis drug interactions

There are 779 drug interactions with Lupkynis (voclosporin).

Lupkynis alcohol/food interactions

There are 2 alcohol/food interactions with Lupkynis (voclosporin).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.